Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma

Neuropediatrics

Volumn 38, Issue 2, 2007, Pages 61-63

  Janzarik, W G ^a   Kratz, C P ^a   Loges, N T ^a   Olbrich, H ^a   Klein, C ^a   Schafer T ^a   Scheurlen, W ^b   Roggendorf, W ^c   Weiller, C ^a   Niemeyer, C ^a   Korinthenberg, R ^a   Pfister, S ^d,e   Omran, H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Cnopf'sche Kinderklinik   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Astrocytoma; RAS; Tumor

Indexed keywords

K RAS PROTEIN; NEUROFIBROMIN; RAS PROTEIN;

ARTICLE; ASTROCYTOMA; CANCER GRADING; GENE; HRAS GEEN; KRAS GENE; NRAS GENE; PATHOGENESIS; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PTPN11 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ASTROCYTOMA; BRAIN NEOPLASMS; EXONS; HUMANS; MUTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 34548726320     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984451     Document Type: Article

References (13)

1. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004; 64: 8816-8820
2. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12: 283-285
3. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, Boom JH van, Eb AJ van der et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-297
4. Burmer GC, Rabinovitch PS, Loeb LA. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ Health Perspect 1991; 93: 27-31
5. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl 2):ii2-11
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
7. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3: 203-209
8. Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32-37
9. Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59: 759-767
10. Sanford RA, Bowman R, Tomita T, Leon G De, Palka P. A 16-year-old male with Noonan's syndrome develops progressive scoliosis and deteriorating gait. Pediatr Neurosurg 1999; 30: 47-52
11. Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005; 65: 1335-1336
12. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Cenet 2003; 34: 148-150
13. Boom J van den, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003; 163: 1033-1043